Docetaxel FDA Link

A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.

Also Known As:

Taxotere; Docetaxel Anhydrous; Docetaxel Hydrate; Docetaxel Trihydrate; Docetaxol; N- Debenzoyl- N- tert- butoxycarbonyl- 10- deacetyltaxol; NSC 628503; RP 56976; RP-56976; Taxoltere Metro; N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol; RP56976; Benzenepropanoic acid, beta- (((1,1- dimethylethoxy)carbonyl)amino)- alpha- hydroxy- , (2aR,4S,4aR,6R,9S,11S,12S,12aS,12bS)- 12b- (acetyloxy)- 12- (benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b- dodecahydro- 4,4a ,6,11- tetrahydroxy- 8,12a,13,13- tetramethyl- 5- oxo- 7,11- methano- 1H- cyclodeca(3,4)benz(1,2- b)oxet- 9- yl ester, (alphaR)-, hydrate (1:3)

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Diterpenes: 1470
      - Taxoids: 2650
        Docetaxel: 12223
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclodecanes
        Taxoids: 2650
        Docetaxel: 12223

Cerys Propert-Lewis Selected Research

Cerys Propert-Lewis Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure